Consequently, the dual-targeted regulation of CXCL4/TGF-β overexpression-mediated immune dysfunction, inflammation, vascular lesions, and skin fibrosis represents a critical therapeutic imperative of SSc. Here, TGFB1 is linked to systemic sclerosis.